Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.
Corfmat M, Willekens C, Vinit J, Bussone G, Fenaux P, Fain O, Klatzmann D, Mekinian A, Comont T; MINHEMON (French network of dysimmune disorders associated to hematological malignancies). Corfmat M, et al. Among authors: klatzmann d. Rheumatology (Oxford). 2021 Jul 1;60(7):3404-3408. doi: 10.1093/rheumatology/keaa696. Rheumatology (Oxford). 2021. PMID: 33164099
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Hartemann A, et al. Among authors: klatzmann d. Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8. Lancet Diabetes Endocrinol. 2013. PMID: 24622415 Clinical Trial.
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D. Rosenzwajg M, et al. Among authors: klatzmann d. Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24. Ann Rheum Dis. 2019. PMID: 30472651 Clinical Trial.
Neutrophil-Platelet and Monocyte-Platelet Aggregates in COVID-19 Patients.
Le Joncour A, Biard L, Vautier M, Bugaut H, Mekinian A, Maalouf G, Vieira M, Marcelin AG, Rosenzwajg M, Klatzmann D, Corvol JC, Paccoud O, Carillion A, Salem JE, Cacoub P, Boulaftali Y, Saadoun D. Le Joncour A, et al. Among authors: klatzmann d. Thromb Haemost. 2020 Dec;120(12):1733-1735. doi: 10.1055/s-0040-1718732. Epub 2020 Oct 29. Thromb Haemost. 2020. PMID: 33124027 Free PMC article. No abstract available.
Interleukin-2 and regulatory T cells in rheumatic diseases.
Kolios AGA, Tsokos GC, Klatzmann D. Kolios AGA, et al. Among authors: klatzmann d. Nat Rev Rheumatol. 2021 Dec;17(12):749-766. doi: 10.1038/s41584-021-00707-x. Epub 2021 Nov 2. Nat Rev Rheumatol. 2021. PMID: 34728817 Review.
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D. Rosenzwajg M, et al. Among authors: klatzmann d. J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26. J Autoimmun. 2015. PMID: 25634360 Free PMC article. Clinical Trial.
382 results